Drug-related deaths in the United Kingdom

Anthem Blue Cross and Blue Shield Foundation Grant Supports Efforts to Address Substance Use Disorder in Northern Virginia

Retrieved on: 
Tuesday, September 6, 2022
Professional Services, Managed Care, Other Health, Health, Philanthropy, General Health, Mental Health, Health Insurance, Fund Raising, Foundation, Insurance, International Overdose Awareness Day, Public health, Health equity, Imprisonment, Food, Awareness, Blue, Drug, Gary Doer, Blue Shield, Topical steroid withdrawal, Blue Cross Blue Shield Association, Anthem (company), Blue Cross, Education, Organization, Foundation, Medicine, Drug-related deaths in the United Kingdom, Housing, United States drug overdose death rates and totals over time, Mental health, Blue Cross (animal charity), Objectivist movement, Transport, Environment, Health, Employment, Child, Pharmaceutical industry, Management, Tutoring

For the past nine years, the Foundation has worked to save lives from overdose and support recovery from substance use disorder.

Key Points: 
  • For the past nine years, the Foundation has worked to save lives from overdose and support recovery from substance use disorder.
  • Substance use disorder is a major public health challenge that affects not only the health of individuals, but entire communities, said Dr. Anne Fedyszen, Behavioral Health Medical Director at Anthem Blue Cross and Blue Shield.
  • Since then, they have offered free recovery support services, resources, and education to individuals in Northern Virginia and Washington, D.C.
  • The Blue Cross and Blue Shield names and symbol are registered marks of the Blue Cross and Blue Shield Association.

M. Justin Coffey, M.D. joins Workit Health as Chief Medical Officer

Retrieved on: 
Thursday, June 30, 2022
Geisinger Health System, Science, American, American Neuropsychiatric Association, Foundation (nonprofit), Menninger Foundation, Neuropsychiatry, American College of Psychiatrists, Goal, History, Drug-related deaths in the United Kingdom, Neurology, Philosophy, Suicide, American Psychiatric Association, University, ECT, Psychiatry, Medicine, ANN, Time, American College, Chicago (franchise), International Society, Collection

ANN ARBOR, Mich., June 30, 2022 /PRNewswire-PRWeb/ -- Workit Health, the nation's leading provider of virtual substance use disorder treatment, has added M. Justin Coffey, M.D. as chief medical officer. Dr. Coffey is a neuropsychiatrist and one of the nation's leading experts in psychiatry and behavioral health. He will bring extensive experience developing and leading a wide range of clinical, educational, and scientific programs to the innovative, person-centered care at Workit.

Key Points: 
  • "Workit Health is on the cutting-edge of person-centered care," said Coffey.
  • "By bringing individuals and families to the design table, Workit is setting a new standard for whole-person behavioral health care.
  • Prior to joining Workit Health, Coffey served as chair of psychiatry and behavioral health at Geisinger Health System, a large, integrated health system in Pennsylvania known for innovation.
  • "Dr. Coffey is an innovative leader who has dedicated his time and expertise to improving behavioral health care," said Lisa McLaughlin, co-CEO and co-founder of Workit Health.

Inmar Intelligence Granted Approval as a Drug Take Back Program Operator by New York State

Retrieved on: 
Monday, June 13, 2022
Accident, Death, New, New York State Department of Health, Awareness, Program, Pharmacy, Drug Enforcement Administration, Sexual abuse, Drug-related deaths in the United Kingdom, Analytics, Drug, LinkedIn, AI, Health care, OXO-biodegradation, Partnership, The New York Times, Government, GLOBE, Machine learning, Solution, Twitter, Industry, Collection, History, Prescription, Human back, National, Safety, Health insurance, Pharmaceutical industry, Cryptocurrency, Facebook

Despite a pervasive number of drug-related deaths year over year, old or unused prescriptions rarely find their way to a secure drug take-back location. In a 2021 Inmar National Survey on Consumer Drug Take-Back Awareness, 73% of respondents reported that they have unused, leftover, or expired medications in their homes. With the State of New York’s approval, Inmar Intelligence will begin executing a program that includes a network of easily accessible collection receptacles that community members can use to safely and appropriately dispose of their unwanted prescription medications -- preventing drug misuse, accidental drug poisonings, and environmental damage. Participation in this drug take-back initiative is free to pharmacies and consumers, as the program is fully funded by pharmaceutical manufacturers, making safe drug disposal easier than ever.

Key Points: 
  • WINSTON-SALEM, NC, June 13, 2022 (GLOBE NEWSWIRE) -- Inmar Intelligence , an experienced drug stewardship operator and regulatory company, is happy to announce that, as of June 8, 2022 they have received approval from New York State as a Drug Take Back Operator.
  • In 2016 alone, more than 3,000 cases of drug poisoning exposures were reported in children under six years of age in the state of New York according to a report from the New York State Department of Health.
  • Inmar Intelligence is working with the State of New York to expand and enhance consumer drug take-back throughout the state with a compliant, cost effective, and cost consistent solution.
  • We are thrilled to announce the State of New Yorks approval of Inmar Intelligence as a Drug Take Back Operator, said Ann-Marie Daugherty, President of Supplytech at Inmar Intelligence.

Will Recent $32 Billion in Opioid Settlements Prevent Addiction? Vivera Has the Answer

Retrieved on: 
Wednesday, March 9, 2022
McKesson Corporation, Purdue Pharma, AmerisourceBergen, Drug-related deaths in the United Kingdom, Physician, Compliance, Company, Chronic pain, Risk, Drug, Name, Communication, AI, Korea Disease Control and Prevention Agency, Pharmacy, Cardinal Health, Pain, CDC, Patient, Pharmacist, Chief executive officer, Technology, Ecosystem, Drug overdose, Johnson & Johnson, Death, Caregiver, Insurance, Neuroscience, CEO, Center, Pharmaceutical industry, Risk management

Vivera has long understood that to tackle the opioid crisis, we first need to prevent addiction from occurring in the first place.

Key Points: 
  • Vivera has long understood that to tackle the opioid crisis, we first need to prevent addiction from occurring in the first place.
  • About 25 percent of patients who are prescribed opiates for chronic pain misuse them, and about ten percent of patients taking opioids for chronic pain develop an opioid use disorder.
  • Ultimately, opioids are killing over 100 Americans every day and are a factor in 7 out of every ten overdose deaths.
  • "Nearly everyone has been directly affected by or knows someone who has been affected by addiction," said Paul Edalat, Chairman and CEO of Vivera.